Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $72.00 at Oppenheimer

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price objective boosted by Oppenheimer from $65.00 to $72.00 in a research note published on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

Separately, The Goldman Sachs Group boosted their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $55.60.

Tarsus Pharmaceuticals Trading Down 0.7 %

NASDAQ TARS opened at $48.78 on Wednesday. The business’s fifty day moving average is $51.04 and its 200-day moving average is $38.94. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -12.80 and a beta of 1.02. Tarsus Pharmaceuticals has a one year low of $20.08 and a one year high of $57.14.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several large investors have recently modified their holdings of TARS. Hsbc Holdings PLC bought a new position in Tarsus Pharmaceuticals in the 2nd quarter worth approximately $241,000. Canada Pension Plan Investment Board bought a new position in shares of Tarsus Pharmaceuticals in the second quarter worth $114,000. Profund Advisors LLC grew its position in shares of Tarsus Pharmaceuticals by 26.8% in the second quarter. Profund Advisors LLC now owns 9,126 shares of the company’s stock valued at $248,000 after purchasing an additional 1,929 shares in the last quarter. Alpha DNA Investment Management LLC raised its stake in shares of Tarsus Pharmaceuticals by 9.1% during the 2nd quarter. Alpha DNA Investment Management LLC now owns 15,174 shares of the company’s stock valued at $412,000 after purchasing an additional 1,261 shares during the period. Finally, Deerfield Management Company L.P. Series C purchased a new stake in Tarsus Pharmaceuticals during the 2nd quarter worth about $273,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.